Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma
ISRCTN15028850Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Jun 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of selinexor in multiple myeloma (MM), sponsored by University of Leeds. Primary endpoint: Progression-free survival at 6 months. Started Jun 2018; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN15028850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15028850.